Subclinical inflammation in relation to insulin resistance in prediabetic subjects with nonalcoholic fatty liver disease

BMC Research Notes

Volumn 9, Issue 1, 2016, Pages

  Hossain, Israt Ara ^a   Akter, Salima ^a   Bhuiyan, Farjana Rahman ^a   Shah, Mijanur Rahman ^b   Rahman, Mohammad Khalilur ^c   Ali, Liaquat ^a  

^a BANGLADESH UNIVERSITY OF HEALTH SCIENCES   (Bangladesh)

^b BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

^c UNIVERSITY OF DHAKA   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; COMPLICATION; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDIABETIC STATE;

EID: 84969150622     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/s13104-016-2071-x     Document Type: Article

References (30)

1. Rahman MH, Hafizur RM, Nahar Q, Khan AR, Ali L. Insulin secretion and sensitivity in Bangladeshi prediabetic subjects. J Diabetes Complicat. 2010;24(1):37-42.
2. Lautamäki R, Borra R, Iozzo P, Komu M, Lehtimäki T, Salmi M, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2006;291(2):282-90.
3. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54.
4. Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract. 2009;84(1):84-91.
5. Neuman G, Sagi R, Shalitin S, Reif S. Serum inflammatory markers in overweight children and adolescents with non-alcoholic fatty liver disease. Isr Med Assoc J. 2010;12(7):410-5.
6. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87(7):3023-8.
7. Utzschneider KM, Kahn SE. The role of insulin resistance in non-alcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91(12):4753-61.
8. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF Consultation. Geneva: World Health Organization. http/ www.who.int/diabetes/publications/diagnosis-diabetes2006
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
10. Jou JM, Lewis SM, Brigys C. ICSH review of the measurement of the erythocyte sedimentation rate. Int J lab Hematol. 2011;33(2):125-32.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.
12. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-50.
13. Bailar JC 3rd, Mosteller F. Guidelines for statistical reporting in articles for medical journals amplifications and explanations. Ann Intern Med. 1988;108(2):266-73.
14. Schor S, Karten I. Statistical evaluation of medical journal manuscripts. JAMA. 1966;195:1123-8.
15. Knofczynski GT, Mundfrom D. Sample sizes when using multiple linear regression for prediction. EPM. 2008;68(3):431-42.
16. Altman DG. Statistics in medical journals: developments in the 1980s. Stat Med. 1991;10:1897-913.
17. Gupte P. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004;19(8):854-8.
18. Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009;57:205-10.
19. Sun Zheng, Lazaremail Mitchell A. Dissociating fatty liver and diabetes. Trends Endocrinol Metab. 2013;24(1):4-12.
20. Agarwal AK, Jain V, Singla S, Baruah BP, Arya V, Yadav R, et al. Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J Assoc Physicians India. 2011;59:351-4.
21. Ruckert IM, Heier M, Rathmann W, Baumeister SE, Doring A, Meisinger C, et al. Association between markers of fatty liver disease and impaired glucose regulation in men and women from the general population: the KORA-F4-Study. PLoS ONE. 2011;6(8):1-11.
22. Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-Ayuso RM, et al. Nonalcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int. 2009;29(1):82-8.
23. Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 2004;19(6):694-8.
24. Koruk M, Taysi S, Savas MC, Yilmaz O, Akçay F, Karakök M, et al. Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turk J Gastroenterol. 2003;14(1):12-7.
25. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, et al. High sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007;42(7):573-82.
26. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46(2):582-9.
27. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2005;25(1):193-7.
28. Kogiso T, Moriyoshi Y, Shimizu S, Nagahara H, Shiratori K. High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the akaike information criterion scoring system in the general Japanese population. J Gastroenterol. 2009;44(4):313-21.
29. Gao Mingming, Ma Yongjie, Liu Dexi. High-fat diet-induced adiposity, adipose inflammation, hepatic steatosis and hyperinsulinemia in outbred CD-1 mice. PLoS ONE. 2015;10(3):e0119784.
30. Strissel KJ, Stancheva Z, Miyoshi H, Perfield JW, DeFuria J, Jick Z, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes. 2007;56(12):2910-8.